SERA

Sera is a clinical-stage molecular-diagnostics company whose entire equity story rests on one product, the PreTRM preterm-birth test, and the PRIME study cited throughout the 10-K. Despite being public for years, it remains effectively pre-commercial: FY2025 revenue was just $81.0K, and the five-year history shows revenue going nowhere — $82K (2021) → $268K → a $306K peak in 2023 → $77K → $81K. That is not a ramp; it is a stalled launch. The P/S of 1065x isn't a valuation signal, it's a flashing light that the $86.3M market cap is pricing future commercialization and reimbursement that have not yet materialized. The MD&A's own forward-looking list — 'market acceptance of our PreTRM test,' 'new CPT codes and their payment rates,' and 'our ability to obtain funding for our operations' — tells you exactly which unproven levers the entire thesis depends on.

The economics are deeply negative and the funding clock is real. FY2025 operating loss was $36.5M and net loss $31.9M against essentially no revenue (operating margin -45,067%). Operating cash burn ran -$25.6M, yet cash and equivalents are only $3.94M; the company is leaning on the broader current-asset pile of $40.8M (itself down 14.3% YoY) to stay funded, implying roughly a year-and-a-half of runway before another raise. Management has already funded that gap by diluting hard — weighted shares rose 43.7% in a single year — and the Risk Factors and MD&A repeatedly flag the need for additional financing. With an accumulated deficit of $312M, holders have absorbed a decade of cash destruction with little commercial traction to show.